Patient-reported outcome measures for technology assessment: A comparison between three-dimensional conformal and intensity-modulated radiotherapy in prostate cancer

doi:10.5306/wjco.v17.i3.115774

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(25)

(32)

(0)

(1)

(952)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Mar 24, 2026; 17(3): 115774
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.115774

Table 2 Weighted expanded prostate cancer index composite and short form-36 health survey results over time from Generalized Estimating Equation repeated-measures models, adjusted by Gleason score, means (95%CI)

	EPIC urinary incontinence	EPIC urinary irritative/obstructive	EPIC bowel summary	EPIC sexual summary	SF-36 physical component summary	SF-36 mental component summary
Cohort treated with three-dimensional conformal radiotherapy
Pre-treatment	95.1 (92.9-97.4)	95.9 (93.9-98.2)	98.9 (97.5-100.3)	51.9 (47.2-56.3)	51.4 (50.3-52.6)	55.2 (54.2-56.1)
3 months	91.8 (88.6-95.0)^a	89.0 (86.0-92.2)^a	95.3 (92.8-97.8)^a	44.4 (39.4-49.2)^a	51.7 (50.7-52.8)	54.7 (53.6-56.0)
6 months	93.8 (91.0-97.0)	93.7 (91.7-96.1)	96.0 (93.9-98.0)^a	49.6 (44.4-54.7)	51.0 (50.1-51.9)	55.8 (54.9-57.0)
12 months	93.3 (90.9-95.9)	95.8 (94.3-97.4)	94.8 (92.5-97.4)^a	47.4 (42.4-52.9)	50.3 (49.2-51.3)^a	56.2 (55.0-57.4)^a
24 months	92.5 (89.9-95.5)	94.0 (92.2-95.9)	93.7 (91.1-96.4)^a	41.8 (36.1-47.0)^a	48.9 (47.7-50.1)^a	56.1 (55.0-57.3)
36 months	89.3 (86.0-92.5)^a	89.2 (86.2-92.4)^a	92.5 (89.4-96.0)^a	42.1 (36.6-47.6)^a	46.2 (44.8-47.6)^a	54.3 (52.9-55.9)
48 months	90.8 (87.4-94.3)^a	87.3 (83.8-91.2)^a	93.4 (90.8-96.4)^a	34.2 (28.9-39.7)^a	46.0 (44.6-47.5)^a	52.2 (50.4-54.0)^a
60 months	88.6 (84.5-92.6)^a	87.9 (84.4-91.5)^a	94.4 (92.3-96.9)^a	30.7 (26.1-35.2)^a	44.9 (43.3-46.6)^a	53.3 (51.6-55.2)^a
Cohort treated with intensity-modulated radiotherapy
Pre-treatment	92.1 (88.3-95.8)	89.9 (86.3-93.6)	97.9 (96.9-99.0)	62.8 (56.6-70.2)	49.1 (47.0-51.4)	50.8 (48.4-53.3)
3 months	87.3 (82.4-93.2)	82.6 (76.7-88.9)	95.2 (93.1-97.1)^a	49.6 (42.4-57.1)^a	47.3 (45.4-49.3)	53.9 (51.4-56.6)^a
6 months	85.0 (79.7-90.5)^a	88.7 (83.6-94.5)	95.7 (93.0-98.5)	53.2 (46.4-60.1)^a	46.3 (44.5-48.4)^a	54.9 (53.2-56.7)^a^,^b
12 months	89.1 (84.2-94.5)	85.9 (81.4-91.0)	95.0 (93.0-97.1)^a	49.7 (43.5-56.4)^a	46.9 (45.1-48.6)^a	54.4 (52.7-56.3)^a
24 months	91.2 (86.4-96.3)	90.0 (86.2-94.1)	97.6 (96.2-99.1)^b	44.4 (38.1-50.5)^a	47.0 (45.3-49.0)^a	55.2 (53.7-56.9)^a^,^b
36 months	89.5 (84.6-94.3)	91.5 (88.5-94.6)^b	95.4 (93.1-97.4)^a	39.4 (33.1-45.4)^b	45.8 (44.1-47.7)^a	54.4 (52.5-56.5)^a^,^b
48 months	88.0 (82.2-94.5)	93.5 (89.7-96.5)^b	99.0 (96.7-101.7)^b	33.9 (27.7-40.1)^b	43.1 (41.1-45.4)^a	56.2 (54.2-58.3)^a^,^b
60 months	89.3 (84.0-94.8)	90.0 (86.5-93.4)^b	94.1 (91.1-97.9)	33.3 (25.0-40.5)^a	41.9 (39.9-44.2)^a	51.6 (48.9-54.8)

^aP < 0.05 in the comparison of the mean score between pre-treatment and post-treatment.

^bP < 0.05 in the comparison of the mean score change since pre-treatment between patients treated with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy (reference group).

EPIC: Expanded prostate cancer index composite; SF-36: Short form-36 health survey.

Full Size Table

Citation: Mera A, Sancho G, Garin O, Pont À, Pardo Y, Macias V, Hervas A, Cabrera P, Ferrer F, Roselló À, Samper Ots P, García ME, Jové-Teixidó J, Ferrer M, The Multicentric Spanish Group of Clinically Localized Prostate Cancer. Patient-reported outcome measures for technology assessment: A comparison between three-dimensional conformal and intensity-modulated radiotherapy in prostate cancer. World J Clin Oncol 2026; 17(3): 115774
URL: https://www.wjgnet.com/2218-4333/full/v17/i3/115774.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i3.115774

Mera A, Sancho G, Garin O, Pont À, Pardo Y, Macias V, Hervas A, Cabrera P, Ferrer F, Roselló À, Samper Ots P, García ME, Jové-Teixidó J, Ferrer M, The Multicentric Spanish Group of Clinically Localized Prostate Cancer. Patient-reported outcome measures for technology assessment: A comparison between three-dimensional conformal and intensity-modulated radiotherapy in prostate cancer. World J Clin Oncol 2026; 17(3): 115774 [DOI: 10.5306/wjco.v17.i3.115774]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.